Principal Investigator
Dickran Kazandjian
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240778
Clinical Trial Summary
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Myeloma
Contact Information
Phone Number
305-243-2647